Antidepressants safest in pregnancy, ranked by evidence

Ranking by pregnancy safety data

Best safety data / first-line:

• Sertraline (Zoloft): Most-studied SSRI in pregnancy. Large observational cohorts show no consistent increased risk of major congenital malformations. Widely recommended as first-line for pregnant patients requiring antidepressant treatment. Preferred for lactation as well due to minimal breast milk transfer.

• Fluoxetine (Prozac): Extensive data. Long half-life means less risk of neonatal discontinuation but also more exposure to fetus if the drug needs to be stopped. Considered acceptable.

• Citalopram and escitalopram (Celexa, Lexapro): Reasonable safety data. Escitalopram has slightly less data than sertraline but is widely used.

Acceptable / used with monitoring:

• Bupropion (Wellbutrin): Reasonable data. Not associated with major malformations. Sometimes preferred for patients with prior good response or for whom other agents are contraindicated.

• Duloxetine (Cymbalta) and venlafaxine (Effexor): Used in pregnancy but with more caution. Third-trimester exposure associated with neonatal adaptation syndrome (respiratory distress, poor tone, feeding difficulty) in a subset of infants.

• Mirtazapine (Remeron): Less data than SSRIs but no clear safety signals. Sometimes used for patients with prominent insomnia or weight loss.

Generally avoided in early pregnancy:

• Paroxetine (Paxil): FDA Category D (older classification) due to first-trimester cardiac defect associations, particularly ventricular septal defects. Some meta-analyses do not support this association, but the FDA warning remains and paroxetine is generally not first-line for newly pregnant patients. Patients already stable on paroxetine sometimes continue after informed discussion.

Avoided if possible:

• MAOIs (phenelzine, tranylcypromine): Hypertensive crisis risk with dietary tyramine and drug interactions. Rarely used in pregnancy. If required, careful monitoring and dietary compliance essential.

• TCAs (amitriptyline, nortriptyline): Older data, generally considered acceptable but the anticholinergic profile and overdose risk in a population with elevated suicidal risk are considerations.

The untreated depression framing

Every antidepressant discussion during pregnancy needs to compare treatment risk to untreated illness risk. Untreated maternal depression is associated with:

• Preterm birth and low birth weight
• Impaired maternal-infant bonding
• Increased postpartum depression risk
• Increased infant regulatory difficulties
• Maternal suicide (leading cause of maternal death in some datasets)

The relevant comparison is not treatment vs no exposure. It is treatment vs untreated depression, which has its own significant risks. For patients with moderate to severe depression, continuing an antidepressant during pregnancy is often the safer overall decision.

Late-pregnancy considerations

Neonatal adaptation syndrome: 20 to 30 percent of infants exposed to SSRIs in the third trimester show mild, self-limited symptoms (jitteriness, feeding difficulty, respiratory rate irregularity, poor tone) in the first 48 hours. Usually resolves within 2 weeks. Not the same as discontinuation syndrome.

Persistent pulmonary hypertension of the newborn (PPHN): Rare but real association with third-trimester SSRI exposure. Absolute risk about 3 to 6 per 1000 exposed vs 1 to 2 per 1000 unexposed.

Dose reduction in late pregnancy: Not routine. Some clinicians reduce dose in the third trimester to lower neonatal adaptation risk, but the evidence for benefit is weak, and it increases relapse risk in the mother during a high-risk window.

Breastfeeding

Most antidepressants are considered compatible with breastfeeding. Sertraline and paroxetine have the lowest breast milk transfer among SSRIs. Fluoxetine and citalopram have higher transfer but are still generally considered acceptable. Bupropion is used. MAOIs are avoided.

For postpartum depression specifically, see the Zurzuvae (zuranolone) state of practice.

Common questions

Is it safe to take Zoloft during pregnancy? Sertraline (Zoloft) is the most-studied SSRI in pregnancy with reassuring safety data. Not associated with major congenital malformations in large observational cohorts. Considered first-line for pregnant patients requiring antidepressant treatment. For patients on sertraline who become pregnant, continuing is usually recommended over stopping.

Is Prozac safe in pregnancy? Fluoxetine has extensive pregnancy data and is considered acceptable. It has a long half-life (long clearance means the fetus continues to be exposed for weeks after the mother stops), which is a consideration in planning discontinuation. Not first-line preferred but a legitimate option.

Why avoid Paxil in pregnancy? Paroxetine has an FDA warning about first-trimester cardiac defects, particularly ventricular septal defects, based on early studies. Some subsequent research has not confirmed this signal. Guidelines generally advise against initiating paroxetine during pregnancy but sometimes continue it in patients already stable on it after informed discussion.

Can I take Wellbutrin during pregnancy? Bupropion has reasonable pregnancy safety data. Not associated with major malformations in cohort studies. Sometimes preferred for patients with prior good response or those where SSRIs caused significant side effects.

What about the third trimester? 20 to 30 percent of SSRI-exposed infants show mild neonatal adaptation symptoms (jitteriness, feeding difficulty) in the first 48 hours, typically self-limiting. Rare persistent pulmonary hypertension. These risks are weighed against the substantial risks of untreated maternal depression, which include preterm birth and maternal suicide.

Should I stop my antidepressant when I get pregnant? Not automatically. For patients with mild depression in remission for over a year, tapering under supervision is reasonable. For patients with moderate to severe depression or recent episodes, continuing the antidepressant is often the safer overall decision. This is a shared decision-making conversation with the treating clinician.

Are there non-drug options during pregnancy? Yes. Cognitive-behavioral therapy, interpersonal psychotherapy, and mindfulness-based interventions all have evidence for antenatal depression. Bright light therapy has evidence for depression more broadly. rTMS has emerging evidence and is being used in pregnancy in some centers. For severe cases requiring rapid response, ECT during pregnancy has an established (though limited) evidence base.

Related

• Medication in pregnancy (general guide)
• Pregnancy safety psychiatric meds clinician guide
• Zurzuvae (zuranolone) for postpartum depression
• Sertraline drug page
• Fluoxetine drug page
• Paroxetine drug page

Sources

• ACOG Committee Opinion No. 757: Screening for perinatal depression. Obstet Gynecol. 2018.
• Chambers CD, Hernandez-Diaz S, Van Marter LJ, et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med. 2006;354(6):579-587.
• Huybrechts KF, Palmsten K, Avorn J, et al. Antidepressant use in pregnancy and the risk of cardiac defects. N Engl J Med. 2014;370(25):2397-2407.
• Cooper WO, Willy ME, Pont SJ, Ray WA. Increasing use of antidepressants in pregnancy. Am J Obstet Gynecol. 2007;196(6):544.e1-5.
• Yonkers KA, Wisner KL, Stewart DE, et al. The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. Gen Hosp Psychiatry. 2009;31(5):403-413.